Protalix BioTherapeutics

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain FDA approval of a protein produced through plant cell suspension culture based expression.
The Company’s unique expression system represents a new method for developing recombinant proteins in a cost-effective, industrial-scale manner.
Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease, in Phase III clinical trials (BALANCE,BRIDGE and BRIGHT studies); OPRX 106, an orally delivered anti-inflammatory treatment for IBD, and alidornase alfa for the treatment of Cystic Fibrosis, in Phase II clinical trials as well as a pre-clinical program PRX-115,a modified form of uricase to treat Gout.